ND-654 (ND654) is a novel potent, liver-specific acetyl-CoA carboxylase (ACC) inhibitor with IC50 of 3/8 nM for human ACC1/ACC2, respectively.
ND-654 inhibits HepG2 cell fatty acid synthesis with an EC50 of 14 nM, and reduces both rat hepatic malonyl-CoA and rat hepatic fatty acid synthesis with ED50 values of 0.34 mg/kg and 0.30 mg/kg at Cmax, respectively.
ND-654 mimics the effects of ACC phosphorylation inhibits hepatic DNL and the development of HCC.
ND-654 selectively targets the liver and inhibits HCC proliferation, improves survival of tumor-bearing rats when used alone and in combination with the multi-kinase inhibitor sorafenib.
